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Edited by Veli-Pekka LehtoAbstract The hyaloid vascular system (HVS) is a transient net-
work of capillaries that nourishes the embryonic lens and the pri-
mary vitreous of the developing eye. We used proteomic analysis
and immunohistochemical staining to identify activin receptor-
like kinase-1 (ALK1), a type I receptor for transforming growth
factor-b1, during the HVS regression phase. In addition, we
overexpressed ALK1 in corneas implanted with bFGF (basic
ﬁbroblast growth factor) pellets and observed that ALK1 overex-
pression resulted in inhibition of bFGF-induced corneal neovas-
cularization in vivo. Our data suggest that ALK1 may play a
role in HVS regression during ocular development.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The hyaloid vascular system (HVS) is a transient network of
vessels, which traverses the primary vitreous and surrounds the
immature lens of the developing eye. The hyaloid artery ex-
tends from the optic nerve to the embryonic lens, giving rise
to a capillary plexus that surrounds the lens consisting of the
vasa hyaloidea propria (VHP), the tunica vasculosa lentis
(TVL), and the pupillary membrane (PM). Failure of the
HVS to regress in humans can lead to persistent hyperplastic
primary vitreous, which, if untreated, can result in blindness.
The precise mechanisms of the regression of the HVS are still
unclear. Possible mechanisms include apoptosis of the vascular
and endothelial cells [1,2], vitreous-derived regression of the
TVL [3–8], macrophage-associated regression of the TVL [9]
and hyalocyte-associated transforming growth factor-b
(TGF-b) [10].
TGF-b is a potent inhibitor of vascular endothelial cell pro-
liferation [10]. It regulates endothelial proliferation via two
receptor/Smad (mother against decapentaplegic) pathways.
After ligand binding and activation of Type I receptors, signals
are transduced from the membrane to the nucleus via Smads*Corresponding author. Fax: +1 617 573 4300.
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doi:10.1016/j.febslet.2005.08.078[11]. Type I receptors recruit and phosphorylate Smads, such
as Smads2 and 3 by the TbRI/ALK5 type I receptor in re-
sponse to TGF-b, and Smads1, 5, and 8 by the bone morpho-
genetic protein type I receptors [12]. Activin receptor-like
kinase-1 (ALK1) activates Smads1, 5, and 8, which downregu-
late VEGF production. In contrast, ALK5 activates Smads2
and 3, which upregulate VEGF production [13]. Expression
of ALK1 in blood vessels and mutations of the ALK1 gene
in patients with human type II hereditary hemorrhagic telangi-
ectasia, a multi-systemic vascular dysplasia, suggests that
ALK1 may play an important role during normal vascular
development [14].
We used a proteomic approach to investigate the protein
expression and to identify the speciﬁc protein changes associ-
ated with the regression of the HVS. Two-dimensional electro-
phoresis and mass spectrometry of the developing mouse lens
and vitreous identiﬁed ALK1 as a diﬀerentially expressed pro-
tein during HVS regression; immunohistochemical staining
demonstrated the localization of ALK1 in the TVL; and over-
expression of ALK1 in the cornea resulted in inhibition of ba-
sic ﬁbroblast growth factor (bFGF)-induced corneal
neovascularization in vivo.2. Materials and methods
2.1. Mouse anterior tissue preparation for 2-DE gels
For the protein extraction and ALK1 immunolocalization studies,
newborn mice were sacriﬁced on post-natal days 1, 4, and 16. Using
a dry ice bed, frozen mouse eyes were scraped with a blade (Beaver
#15) to remove the cornea, conjunctiva, sclera, ciliary body, uvea,
and retina, leaving the lens surrounded by the PM, TVL, and pri-
mary vitreous (containing VHP). The dry ice bed was used to pre-
vent warming of the specimen, tissue melting and subsequent
protein denaturation. Samples of P1, P4, and P16 were pooled
and independently solubilized in 250 ll of total protein extraction
buﬀer 7 M urea, 2 M thiourea, 1% (w/v) ASB-14 detergent, 40 mM
Tris base, 0.001% bromophenol blue, 20% carrier ampholyte (Biorad
Laboratories, Hercules, CA), and 2 ll of 200 mM tributylphosphine
by mechanically homogenizing them with an electrical tissue homog-
enizer for 5 min on ice. The homogenates of the protein extracts
were cleared by centrifugation for 20 min at 14000 rpm and 4 C
to remove particulates. Protein concentration of the supernatants
was determined by protein assay (Biorad Laboratories). All experi-
ments using animals were conducted in accordance with the Animal
Care and Use Committee guidelines of the Massachusetts Eye and
Ear Inﬁrmary and the Association for Research in Vision and Oph-
thalmology (ARVO) Statement for the Use of Animals in Ophthal-
mic and Vision Research.ation of European Biochemical Societies.
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identiﬁcation
Three samples per post-gestational day were loaded onto non-lin-
ear, immobilized pH gradient (IPG) gel strips (7 cm, pH 3–10), sub-
jected to isoelectric focusing with a programmed voltage gradient at
8000 V for 5 h, and rehydrated overnight with rehydration/sample
buﬀer (Biorad Laboratories). IPG strips were equilibrated with buﬀer
containing 6 M urea, 50 mM Tris (pH 8.8), 30% glycerol, 2% SDS
(sodium dodecyl sulfate), and 0.001% bromophenol blue containing
2% dithiothreitol or 2.5% iodoacetamide. Following equilibration,
second-dimension separation was performed on 4–20% SDS–PAGE
(SDS–polyacrylamide gel electrophoresis gels) (Biorad Laboratories)
with the ﬁrst-dimension IPG strip embedded in 0.5% agarose at the
top. After electrophoresis, the proteins on the gel were ﬁxed in 10%
acetic acid and 20% methanol for 1 h and then stained with SYPRO
Rubin (Biorad Laboratories). Images of the 2-DE (two-dimensional
electrophoresis) gels were captured with Molecular Imager FX Pro
Plus multi-imager system and the protein expression proﬁles at each
time point were compared, in triplicate, using the Phoretix 2D image
analysis software. Protein spots present in P16 with expression level 2-
to 10-fold greater than P1 were considered for protein identiﬁcation.
The statistical signiﬁcance of changes was evaluated using Phoretix
2D software.
Gel bands (diﬀerentially expressed proteins) from 2-DE gels were
excised, minced into approximate 1 mm3 pieces with a sterile razor
blade of the Xcise technology platform from the Proteome system,
alkylated, and digested with trypsin (Promega, Madison, WI). Pep-
tides were resuspended in 50% acetonitrile with 1% formic acid solu-
tion and subjected to nano-LC ESI IT MS/MS analysis. A Surveyor
LC pump (Thermo Electron, San Jose, CA) with a C18 trapping col-
umn (300 lm i.d. · 1 mm, Dionex, Sunnyvale, CA) and a reversed-
phase column 75 lm i.d. · 15 cm (Magic C18AQ, 3 lm) was used
for nano-LC experiments. An LCQ Deca XP plus ESI mass spec-
trometer (Thermo Electron, San Jose, CA) was used for all the
experiments.
MS/MS data-dependent acquisition followed by database searching
with SEQUEST (BioWorks 3.1, Thermo Electron, San Jose, CA) al-
lowed protein identiﬁcation. Fully tryptic peptides were matched with
SEQUEST at a delta correlation (A¨Cn) of greater than 0.08 and cor-
relation (Xcorr) greater than 1.9, 2.2, and 3.5 for charged states of
+1, +2, and +3, respectively. Peptide mass ﬁngerprints were searched
for matches with the virtually generated tryptic protein masses of the
NCBInr mouse protein sequence database (www.ncbi.nml.nih.gov).
All databases were provided in the public domain by the host institu-
tions. Proteins were noted as diﬀerentially expressed if they could not
be located at the corresponding position on the 2-DE gel of the other
time point.
2.3. ALK1 immunolocalization by confocal microscopy
Mouse eyes harvested at P1, P4, and P16 were embedded in optimal
cutting temperature compound (Miles, Elkhart, IN), frozen in liquid
nitrogen, cryostat sectioned, and ﬁxed in acetone for 10 min. After
blocking with 1% bovine serum albumin (BSA) (Sigma Chemical
Co., St. Louis, MO) for 30 min, the sections were incubated for 1 h
with rabbit anti-ALK1 polyclonal antibody (courtesy of Dr. D.A.
Marchuck, University of North Carolina) at a concentration of
1:200. A secondary antibody used was ﬂuorescein-conjugated, aﬃn-
ity-puriﬁed anti-rabbit IgG antibody (Jackson ImmunoResearch Lab-
oratories, West Grove, PA) at a concentration of 1:400. Negative
controls were prepared in the same manner, with 1% BSA without pri-
mary antibody. Immunostained sections were viewed with a Leica TCS
SP2 CLSM confocal laser scanning microscope (Leica, Heidelberg,
Germany).2.4. Plasmid construction and corneal naked DNA injection
pYX-Asc-ALK1 cDNA was purchased from ATCC (Manassas,
VA). Plasmids were puriﬁed using a Qiagen kit (Valencia, CA)
according to the manufacturers instructions. The mouse ALK1
DNA was sequenced and subcloned into pEF expression vector. An
Elongation Factor 1 alpha promoter (pEF) was used to drive the
expression of the ALK1 gene. Mouse corneas received a DNA injec-
tion of 5 ll of pEF-ALK1 (400 ng/ll) or an injection of 5 ll of vector
(400 ng/ll). An antibiotic ophthalmic ointment was used after sur-
gery.2.5. bFGF pellet preparation and corneal micropocket assay
Pellets were made of the slow-release polymer Hydron (polyhydr-
oxyethylmethacrylate), which contained a combination of 45 ng/pel-
let of sucralfate (Sigma) and 120 ng/pellet of bFGF (R&D
Systems, Minneapolis, MN) as previously described by Kenyon
et al. [15].
Brieﬂy, a suspension of sterile saline containing the appropriate
amount of recombinant bFGF and sucralfate was made and speed-
vacuumed for 8 min. To this suspension, 10 ll of 12% Hydron in eth-
anol was added. The suspension was then deposited onto a sterilized
nylon mesh (LAB Pak, Sefar America, Depew, NY) and embedded be-
tween the ﬁbers. The resulting grid of 10 mm · 10 mm squares was
allowed to dry on a sterile Petri dish for 60 min. The ﬁbers of the mesh
were pulled apart under a microscope and, among the approximately
100 pellets produced, 30–40 uniformly-sized pellets of 0.4 · 0.4 ·
0.2 mm were selected for implantation. All procedures were performed
under sterile conditions.
Three days after the naked DNA injections, corneal micropockets
were created with a modiﬁed von Graefe knife in C57BL/6 mice. Hy-
dron pellets containing 120 ng of human bFGF were implanted into
the corneal pockets.
2.6. Measurement of corneal neovascularization
The corneas were routinely examined and photographed in ﬁve
positions: en face, superior, inferior, nasal, and temporal with a slit
lamp biomicroscope (Nikon FS-2, Tokyo, Japan) on days 1, 4, 7,
and 14 post-pellet implantation. The photographs were digitized
and the images were resolved at 300 pixels/in. and analyzed with
the NIH ImageJ image program (NIH, Bethesda, MD). NIH Ima-
geJ program was used to calculate the area of corneal neovascular-
ization areas. Statistical analysis was performed with the Student
t-test.3. Results
3.1. Progressive regression of HVS in the mouse and the
diﬀerential protein expression proﬁle
We designed a time course experiment to examine the
changes in protein expression at P1 and P16 throughout the
HVS regression process. As this is the ﬁrst reported application
of proteomic analysis on HVS regression, several conditions
for tissue selection and preparation were developed and opti-
mized to obtain clean specimens of the lens and vitreous for
2-DE gels.
We generated protein expression maps in triplicate for each
time point, obtaining a reproducible separation of the protein
spots on the 2-DE gels. We could detect up to 1400 protein
spots in each gel with the Phoretix 2D image analysis software
(Fig. 1A). This software allows the possibility to warp diﬀerent
gel images to improve the quality of the protein spot matching
between the gels and allow an easy detection of the diﬀerences
among the gels. We analyzed our 2-DE gels and observed a
progressive decrease in the number and intensity of the protein
spots from P1 to P16, particularly of the migrated proteins in
the area corresponding to pI 4–7 and Mw 30–90 kDa (Fig.
1B–C).
However, the warping of the 2-D gel images of P1 with P16
revealed the presence of a small number of protein spots for
which expression level in P16 was 2- to 10-fold greater than
P1. 20 protein spots were analyzed using mass spectrometry
analysis. Some of these identiﬁed proteins displayed slightly
diﬀerent molecular weights and pIs, suggesting the presence
of diﬀerent isoforms or post-translational modiﬁcations. Eigh-
teen diﬀerentially expressed proteins were identiﬁed, two addi-
tional proteins were unclassiﬁed, and ﬁfteen were unknown.
ALK1 was identiﬁed as spot #17.
Fig. 1. Proteomic analysis of proteins from the lens and vitreous of P1
and P16 mice. The merged image (A) represents the warped image
between P1 (B) and P16 (C) obtained with Phoretix 2D evolution
software. The proteins excised from 2-D gel (P16) for analysis and
identiﬁcation by mass spectrometry are identiﬁed with numbers 1–20
(C).
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microscopy
To investigate whether ALK1 is expressed in TVL during
mouse development, mouse eyes at P1, P4 and P16 were immu-Fig. 2. Confocal immunohistochemical localization of ALK1 in the mouse e
sectioned. Sections of the tunica vasculosa lentis at P1, P4 and P16 were immu
resulting images were merged (B,D,F). The TVL areas are enlarged in Fig. 2nostained with anti-ALK1 antibody. The confocal immunohis-
tochemical staining demonstrated that ALK1 is localized in
the endothelial cells of the TVL at P1, P4, and P16 (Fig. 2A,
C and E).3.3. Naked DNA, pEF-ALK1, blocked bFGF-induced corneal
NV
Naked DNA has been eﬀectively used for the delivery of
DNA into mouse corneas. To assay if ALK1 can inhibit
bFGF-induced corneal NV (neovascularization), mouse cor-
neas were injected with naked DNAs of pEF (vector) and
pEF-ALK1. The ALK1 plus pellet group (Fig. 3M–P) showed
no evidence of corneal NV at any time point after pellet
implantation. The group receiving vector control plus pellets
(Fig. 3I–L) began to develop corneal NV at day 4, and the
new vessels continued to grow toward the pellet area at days
7 and 14. The area occupied by NV in the ALK1 treated mice
was 0.58 and 0.47 mm2 at days 7 and 14 after bFGF pellet
implantation, respectively (Fig. 3O–P). This was signiﬁcantly
less than the NV areas in vector treated mice, which were
3.14 mm2 (p = 0.001) and 3.33 mm2 (p = 0.001) at 7 and 14
days after bFGF pellet implantation, respectively (Fig. 3K–
L). The no-pellet control groups [ALK1 naked DNA
(Fig. 3E–H) and vector naked DNA (Fig. 3A–D)] did not in-
duce corneal NV.4. Discussion
Genetic studies in mice and humans have demonstrated that
the TGF-b signaling pathway plays an important role in the
maintenance of vascular homeostasis during embryogenesis
and during adult life [16]. Depending on the experimental con-
ditions, TGF-b may act as an inhibitor or a stimulator of angi-
ogenesis in vitro and in vivo [17,18]. However, the molecular
mechanisms and target cells by which the pleiotropic TGF-b
elicits its pro- and anti-angiogenic properties remain unclear
[13].
ALK1 is one of the seven Type I receptors for the TGF-b
family of proteins [19]. Its expression has been detected in endo-
thelial cells of highly vascularized tissues (lungs and placenta)
[20], normal and neoplastic pituitary cells [21], anaplastic largeye during development. Mouse eyes at postnatal days 1, 4 and 16 were
nostained with anti-ALK1 antibodies (A,C,E) and PI staining, and the
B1, D1 and F1.
Fig. 3. bFGF-induced corneal NV is inhibited by naked ALK1 DNA
injection in vivo. No-pellet controls are shown in A–H: Injection of
naked DNA [ALK1 (E–H) and vector only (A–D)] did not induce
corneal NV. The vector plus pellet positive controls are shown in I–L:
Development of NV in the corneal stroma was evident by day 4 (J);
new vessels continued to grow in the direction of the pellet on days 7
and 14. None of the mice in the ALK1 and pellet groups (M–P)
showed development of corneal NV on days 1, 4, 7, and 14 after pellet
implantation. Asterisk (\) indicates pellet implantation. The area of
corneal NV of the four groups at days 1–14 is shown (Q).
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and central nervous system cells [24]. ALK1 transduces the
TGF-b1 signal by phosphorylating Smad1, Smad5, or Smad8
[13,14]. Upon phosphorylation by the receptors, Smad com-
plexes translocate into the nucleus, where they cooperate with
sequence-speciﬁc transcription factors in the promoter DNA
to regulate gene expression [12]. This functional and physical
interaction confers both speciﬁcity and complexity in transcrip-
tional responses to TGF-b family ligands [12].
Mutations of the ALK1 or endoglin genes have been linked
to the human vascular disorder Hereditary Hemorrhagic Tel-
angiectasia (HHT) [25,26]. This is an autosomal-dominant
disorder, also known as Osler-Rendu-Weber syndrome,
characterized by the age-dependent development of focal
arteriovenous malformations and telangiectases [27]. HHT
type 2 is caused by loss of function of the activin receptor-
like kinase 1 (ACVRL1 or ALK1) [27]. The disease is charac-
terized by dilated, thin-walled, vascular anomalies of the skin
and mucous membranes and recurrent epistaxis. In literature,abnormal eye disorders have been documented in 45–65%
of patients with HHT, with the most common lesions being
conjunctival telangiectasias [28,29]. Retinal arteriovenous
malformations, retinal telangiectasia and choroidal haem-
orrhage during intraocular surgery have also been noted
[28,30].
Identiﬁcation of ALK1 by proteomic analysis and immuno-
histochemistry in our model of HVS regression is consistent
with Luttys observation that the TGF-b1 pathway may play
an important role in the remodeling of ocular vasculature
[10]. However, the exact role of ALK1 in angiogenesis remains
controversial. Goumans et al. [13] suggested that the constitu-
tively active form of ALK1 promotes endothelial cell migra-
tion and proliferation by upregulating Id-1, a transcription
factor promoting vascular growth through repression of
thrombospondin-1.
Lamouille et al. [31] have suggested that ALK1 is implicated
in the maturation phase of angiogenesis. They showed that the
transfection of a constitutively active form of ALK1 (which re-
sults in a constitutive ligand-independent receptor activation)
inhibits both endothelial cell proliferation at the G1 phase of
the cell cycle and endothelial cell migration through a
modiﬁcation of the dynamics of the endothelial cell cytoskele-
ton. Consistent with these results, a zebraﬁsh ALK1 mutant,
vgb, whose vessel dilation phenotype is reminiscent of that of
the ALK1/ mice, showed an increased number of
endothelial cells within the aﬀected vessels, suggesting the role
of ALK1 in the inhibition of endothelial cell proliferation
[32].
Several studies have reported that ALK1 stimulates the res-
olution phase of angiogenesis. Oh et al. [14] observed that
ALK1 deﬁcient (/) embryos die at midgestation and exhibit
severe vascular abnormalities characterized by excessive fusion
of capillary plexes into cavernous vessels and hyperdilation of
large vessels. They suggested that ALK1 plays a role in the
inhibition of endothelial cell proliferation and in the stabiliza-
tion of vessel structural integrity.
In their studies of the ALK1 expression patterns during
wound healing, Seki et al. [11] showed that ALK1 was almost
undetectable in the numerous capillaries that had formed in
the area surrounding the wound. This evidence also supports
the role of ALK1 in the resolution phase rather than the acti-
vation phase of angiogenesis. The discrepancies between the
ascribed roles of ALK1 in diﬀerent studies may be due to dif-
ferences in the cell lines and cultures used or possible second-
ary adaptive processes that may take place in the embryo
during development in order to counteract the lack of ALK1
expression [33].
Lebrin et al. [34] clariﬁed these conﬂicting reports about
ALK1 function presenting the activity of endoglin as modula-
tor of the balance between TGF-b1/ALK1 and TGF-b1/ALK5
signaling pathways. They showed how endoglin induces endo-
thelial cell proliferation and migration, promoting an eﬃcient
TGF-b1/ALK1 interaction. In the absence of endoglin,
endothelial cells do not proliferate and ALK1 signaling is
abrogated; unopposed ALK5 signaling maintains the endothe-
lium quiescence [33].
The model of pellet-induced corneal NV used in our exper-
iment is especially advantageous because it is reproducible
and it facilitates investigation of angiogenesis in various mur-
ine tumor models as well as in genetically deﬁned murine
strains [15]. This model has been used to conﬁrm the anti-
E. Albe` et al. / FEBS Letters 579 (2005) 5481–5486 5485angiogenic activity of several anti-angiogenic factors including
angiostatin [35], endostatin [36,37], PEDF [38], and neostatin
[39]. With this in vivo model, we demonstrated that an overex-
pression of ALK1 in the mouse cornea (through naked DNA
injection) does not induce corneal NV and can prevent the
growth of bFGF-induced new stromal vessels. Our results
showing the anti-angiogenic activity of ALK1 are of particular
interest given its role in HVS regression.
As the hyaloid vessels are arteries, our ﬁndings are consistent
with those of Seki et al. [11] showing that ALK1 expression is
induced in the pre-existing feeding arteries and newly forming
arterial vessels in wound healing and tumor angiogenesis, but
is greatly diminished in adult arteries, suggesting that the
expression of ALK1 may play an important role in the arteri-
alization phase mediating the TGF-b1 signal. Supporting this
view, ALK1 KO mice suﬀer from generalized developmental
arrest by E10.5 due to defects in vascular smooth muscle cell
diﬀerentiation and recruitment [40]. Better understanding of
the mechanisms of ALK1 activation may provide the basis
for future therapeutic interventions to prevent and treat ocular
NV.
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Diﬀerential protein expression at post-gestational day 16.SPOT # Protein Name1 RAD50 homolog2 Olfactory receptor GA_x6K02T2PBJ9-
6773690-67746283 Coﬁlin 1, non-muscle4 Guanine nucleotide-binding protein,
b-1 subunit
5 Protein kinase, cAMP dependent regulatory,
type I b
6 a enolase (2-phospho-D-glycerate
hydro-lyase) (non-neural enolase)7 Cathepsin 3 precursor8 Unclassiﬁed9 Knsl7 protein10 F-box/LRR-repeat protein 3B
(F-box and leucine-rich repeat protein)11 Enolase 3, b muscle
12 Albumin 113 Heat shock cognate 71 kDa protein14 Fatty acid binding protein 5,
epidermal; keratinocyte lipid
binding protein15 Vimentin16 Tubulin, b 2
17 ALK1 protein18 CRAA_MOUSE a crystallin A chain,
major component19 Crystallin, b A4
20 UnclassiﬁedReferences
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